By Sabela Ojea
INmune Bio said its XPro1595 inhibitor has demonstrated remyelination, a natural process that restores myelin, in an animal model of demyelinating disease.
The clinical-stage company said the multi-year study, published in a seminal paper in the journal Cell Reports, has implications for many central nervous system diseases such as Alzheimer's.
Myelin is necessary for fast and efficient communication between neurons, the company said.
INmune expects to report top-line cognitive results of an ongoing blinded randomized Phase II in early Alzheimer disease patients in the first half of 2025.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
October 24, 2024 15:25 ET (19:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。